cyclopentolate (cyclogyl) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cyclopentolate (cyclopentolate hydrochloride) is a parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia. This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0860 - $10.1200
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( phenylephrine (Prefrin), cyclopentolate (cyclogyl) )

Alternative names

1-hydroxy-alpha-phenylcyclopentaneacetic acid 2-(dimethylamino)ethyl ester | 2-(dimethylamino)ethyl 1-hydroxy-alpha-phenylcyclopentaneacetate | 2-(dimethylamino)ethyl 2-(1-hydroxycyclopentyl)-2-phenylacetate | 2-phenyl-2-(1-hydroxycyclopentyl)ethanoic acid beta-(dimethylamino)ethyl ester | akpentolate | ak-pentolate | alnide | alpha-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester | beta-(dimethylamino)ethyl (1-hydroxycyclopentyl)phenylacetate | beta-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate | ciclopentolato | cyclogyl | cyclopentolate | (+-)-cyclopentolate | (±)-cyclopentolate | cyclopentolate hcl | cyclopentolatehydrochloride | cyclopentolate hydrochloride | cyclopentolatum | cyclopentylate | mydrilate | penolair | pentolair | α-(1-hydroxycyclopentyl)benzeneacetic acid 2-(dimethylamino)ethyl ester | β-dimethylaminoethyl (1-hydroxycyclopentyl)phenylacetate

Organizations (23)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (7)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (11)

Approved Indications (2)


 

Eye Diseases (approved 1994)

Mydriasis

Experimental Indications - Clinical Trial Phases 1-4 (11)


 

Cataract (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Esotropia (Phase 4)

Eye Diseases (Phase 4)

Keratitis (Phase 3)

Miosis (Phase 2)

Mydriasis (Phase 4)

Myopia (Phase 1)

Refractive Errors (Phase 4)

Retinopathy of Prematurity (Phase 4)

Vision Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 13
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue